0001181431-11-029016.txt : 20110512
0001181431-11-029016.hdr.sgml : 20110512
20110512103744
ACCESSION NUMBER: 0001181431-11-029016
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20110511
FILED AS OF DATE: 20110512
DATE AS OF CHANGE: 20110512
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BONDURANT STUART
CENTRAL INDEX KEY: 0001181152
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34641
FILM NUMBER: 11834255
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Furiex Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001484478
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 271197863
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3900 PARAMOUNT PARKWAY
STREET 2: SUITE 150
CITY: MORRISVILLE
STATE: NC
ZIP: 27560
BUSINESS PHONE: 919-456-7800
MAIL ADDRESS:
STREET 1: 3900 PARAMOUNT PARKWAY
STREET 2: SUITE 150
CITY: MORRISVILLE
STATE: NC
ZIP: 27560
FORMER COMPANY:
FORMER CONFORMED NAME: PPD Therapeutics, Inc.
DATE OF NAME CHANGE: 20100218
4
1
rrd311326.xml
FORM 4
X0303
4
2011-05-11
0
0001484478
Furiex Pharmaceuticals, Inc.
FURX
0001181152
BONDURANT STUART
C/O FURIEX PHARMACEUTICALS, INC.
3900 PARAMOUNT PARKWAY, SUITE 150
MORRISVILLE
NC
27560
1
0
0
0
Common Stock
2011-05-11
4
P
0
3300
15.2496
A
3896
D
Stock Options (to buy)
9.11
2020-06-17
Common Stock
17570
17570
D
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.24 to $15.25, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
The options were awarded on 6/17/2010 and vest and become exercisable in full on the earlier of the first anniversary of the date of grant or immediately prior to the next election of directors of the Company, provided that the Optionee is still at that time serving on the Company's Board of Directors.
/s/ Stuart Bondurant
2011-05-11